We caught up with Editorial Board member Dr Assaf Hilely (Tel Aviv Medical Center, Tel Aviv, Israel), who talked us through his recent study of non-neovascular age-related macular degeneration with subretinal fluid.
- What prognostic factors are currently used to guide treatment when initiating anti-vascular endothelial growth factor treatment for patients with age-related macular degeneration (AMD) with and without neovascularisation? (00:07)
- What was the rationale for investigating patterns of subretinal fluid in eyes with AMD without neovascularisation? (01:22)
- Could you tell us a little about the aims and design of your recent study? (02:12)
- What were the findings of the study? (03:20)
- What will be the impact of these findings on clinical practice and what future studies are planned? (04:53)
Speaker Disclosure: Dr Assaf Hilely has no financial or non-financial relationships or activities to declare in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of ESCRS 2020.
Share this Video
Related Videos In Macular Degeneration
Carl Regillo, Hawaiian Eye 2022: Emerging Therapies for Wet Age-related Macular Degeneration
There are new treatment options for patients with wet age-related macular degeneration emerging, according to a presentation at Hawaiian Eye 2022. It was a pleasure to speak with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA) about his views on the latest treatments to emerge for wet age-related macular degeneration. The abstract entitled Update […]
Carl Regillo, Hawaiian Eye 2022: Ranibizumab Injection for the Treatment of Wet Age-related Macular Degeneration
A new ranibizumab injection offers hope for patients with wet age-related macular degeneration, according to a presentation at Hawaiian Eye 2022. It was great to catch up with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA), who talked to us about the ranibizumab injection and its advantages over anti-vascular endothelial growth factor injections. The […]
Kyoko Ohno-Matsui, EURETINA 2021: Advantages and Limitations of a Deep Learning Algorithm
We were delighted to speak with Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan) about the potential advantages and limitations of a deep learning algorithm for automated detection of myopic maculopathy and pathologic myopia in fundus images, and the challenges in developing this algorithm. Questions What are the potential advantages and limitations of a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!